The first patient has been enrolled in Encore Vision’s phase 1/2 trial of EV06, an investigational topical treatment for presbyopia, according to a company press release. EV06 (lipoic acid choline ester) is a compound being developed to reverse age-related changes in the crystalline lens that result in diminished lens elasticity.
A new study compares outcomes between these two drugs in previously untreated patients with neovascular AMD. How do they stack up? BMC Ophthalmology
Significant racial, ethnic and socioeconomic disparities appeared to exist in the care and outcome of pediatric patients with retinoblastoma, according to the results of a population study.Specifically, lower socioeconomic status appeared negatively as…
SPK-RPE65, a potential gene therapy treatment for RPE65-mediated inherited retinal dystrophies, has met its primary endpoint of demonstrating improvement in visual function as measured by the change in bilateral mobility testing between baseline and 1 year in a phase 3 pivotal trial, according to a press release from Spark Therapeutics. Patients who received SPK-RPE65 outperformed controls in the two secondary endpoints of full-light sensitivity threshold testing (P
Dr Gil Binenbaum discusses his recent study that aimed to determine the best evidence-based practices for screening for ocular complications in children with diabetes. CHOP Expert Commentary
(MedPage Today) — Case Findings: A 70 year old man presents with blurred vision and a nasal field defect in one of his eyes. Prior to arriving in the emergency department, he saw flashes of light and floaters, accompanied by a shower of black dots blo…